Human CD59 inhibitor sensitizes rituximab resistant lymphoma cells to complement-mediated cytolysis

Rituximab efficacy in cancer therapy depends in part on induction of complement-dependent cytotoxicity (CDC). Human CD59 (hCD59) is a key complement regulatory protein that restricts the formation of the membrane attack complex, thereby inhibiting induction of CDC. hCD59 is highly expressed in B-cel...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Hu, Weiguo, Ge, Xiaowen, You, Tao, Xu, Ting, Zhang, Jinyan, Wu, Gongxiong, Peng, Zhihai, Chorev, Michael, Aktas, Bertal H., Halperin, Jose A., Brown, Jennifer R, Qin, Xuebin
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2011
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3622284/
https://ncbi.nlm.nih.gov/pubmed/21252115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-10-3016
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller